嵌合抗原受体T细胞治疗安全性研究进展

Progress in the safety of chimeric antigen receptor T cells therapy

嵌合抗原受体T细胞(CAR-T)治疗进展迅速,其安全性问题一直受到广泛关注。第62届美国血液学会年会上针对其主要不良反应的发生机制、预测指标及治疗策略进行了一系列报道,对全面提高CAR-T治疗的安全性具有一定的指导意义。

Chimeric antigen receptor T cells(CAR-T)therapy is progressing rapidly,and its safety has been widely concerned.At the 62nd American Society of Hematology Annual Meeting,a series of reports on the mechanism,predictive indicators and treatment strategies of major adverse reactions were carried out.These reports have certain guiding significance for comprehensively improving the safety of CAR-T therapy.